889 related articles for article (PubMed ID: 31432604)
1. Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease.
Trist BG; Hare DJ; Double KL
Aging Cell; 2019 Dec; 18(6):e13031. PubMed ID: 31432604
[TBL] [Abstract][Full Text] [Related]
2. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
4. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
5. The interplay between neuroinflammatory pathways and Parkinson's disease.
Eser P; Kocabicak E; Bekar A; Temel Y
Exp Neurol; 2024 Feb; 372():114644. PubMed ID: 38061555
[TBL] [Abstract][Full Text] [Related]
6. Age and Parkinson's disease-related neuronal death in the substantia nigra pars compacta.
Eriksen N; Stark AK; Pakkenberg B
J Neural Transm Suppl; 2009; (73):203-13. PubMed ID: 20411779
[TBL] [Abstract][Full Text] [Related]
7. Co-Expression of Nogo-A in Dopaminergic Neurons of the Human Substantia Nigra Pars Compacta Is Reduced in Parkinson's Disease.
Eyer GC; Di Santo S; Hewer E; Andereggen L; Seiler S; Widmer HR
Cells; 2021 Nov; 10(12):. PubMed ID: 34943877
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
9. Detrimental deletions: mitochondria, aging and Parkinson's disease.
Biskup S; Moore DJ
Bioessays; 2006 Oct; 28(10):963-7. PubMed ID: 16998822
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress and Parkinson's disease.
Owen AD; Schapira AH; Jenner P; Marsden CD
Ann N Y Acad Sci; 1996 Jun; 786():217-23. PubMed ID: 8687021
[TBL] [Abstract][Full Text] [Related]
11. [Pathological mechanisms of Parkinson's disease].
Matsui H; Takahashi R
Brain Nerve; 2009 Apr; 61(4):441-6. PubMed ID: 19378814
[TBL] [Abstract][Full Text] [Related]
12. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
13. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
14. The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease.
Hastings TG
J Bioenerg Biomembr; 2009 Dec; 41(6):469-72. PubMed ID: 19967436
[TBL] [Abstract][Full Text] [Related]
15. The origins of oxidant stress in Parkinson's disease and therapeutic strategies.
Surmeier DJ; Guzman JN; Sanchez-Padilla J; Goldberg JA
Antioxid Redox Signal; 2011 Apr; 14(7):1289-301. PubMed ID: 20712409
[TBL] [Abstract][Full Text] [Related]
16. Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.
Surmeier DJ; Halliday GM; Simuni T
Exp Neurol; 2017 Dec; 298(Pt B):202-209. PubMed ID: 28780195
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial Dysfunction Combined with High Calcium Load Leads to Impaired Antioxidant Defense Underlying the Selective Loss of Nigral Dopaminergic Neurons.
Ricke KM; Paß T; Kimoloi S; Fährmann K; Jüngst C; Schauss A; Baris OR; Aradjanski M; Trifunovic A; Eriksson Faelker TM; Bergami M; Wiesner RJ
J Neurosci; 2020 Feb; 40(9):1975-1986. PubMed ID: 32005765
[TBL] [Abstract][Full Text] [Related]
18. What process causes nigral cell death in Parkinson's disease?
Jenner P
Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
[TBL] [Abstract][Full Text] [Related]
19. Neuronal vulnerability in Parkinson's disease.
Double KL
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
[TBL] [Abstract][Full Text] [Related]
20. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.
Surmeier DJ; Guzman JN; Sanchez-Padilla J
Cell Calcium; 2010 Feb; 47(2):175-82. PubMed ID: 20053445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
